Last updated on November 2018

Efficacy Safety and Pharmacokinetics of Topical Timolol in Infants With Infantile Hemangioma (IH)

Brief description of study

The purpose of this study is to assess the safety and efficacy of Timolol 0.25% and 0.5% doses.

Detailed Study Description

Primary: Describe the efficacy of 0.25% and 0.5% topical timolol maleate GFS as assessed through IH changes in volume. Secondary: Describe the safety and PK of topical timolol maleate GFS for treatment of IH.

Clinical Study Identifier: NCT02913612

Contact Investigators or Research Sites near you

Start Over

Sarah Chamlin, MD

Ann and Robert H. Lurie Children's Hospital of Chicago
Chicago, IL United States
  Connect »

Anita Haggstrom, MD

Indiana University Health
Indianapolis, IN United States
  Connect »

Chiara Melloni, MD, MHS

Johns Hopkins Medical Center
Baltimore, MD United States
  Connect »

Marilyn Liang, MD

Boston Children's Hospital
Boston, MA United States
  Connect »

Megha Tollefson, MD

Mayo Clinic
Rochester, MN United States
  Connect »

Maria Garzon, MD

Columbia University Medical Center
New York, NY United States
  Connect »

Adrienne Hammill, MD

Cincinnati Children's Hospital Medical Center
Cincinnati, OH United States
  Connect »

Chiara Melloni, MD, MHS

Children's Hospital of Philadephia
Philadelphia, PA United States
  Connect »

Adelaide Hebert, MD

The University of Texas Medical School at Houston
Houston, TX United States
  Connect »

Beth Drolet, MD

Medical College of Wisconsin
Milwaukee, WI United States
  Connect »

Julianne Mann, MD

Dartmouth-Hitchcock Medical Center
Lebanon, NH United States
  Connect »

Darvy Mann, MD

DCOL Center for Clinical Research
Longview, TX United States
  Connect »